Although the number of anti-infective vaccines entering clinical study each year since 2000 has been higher on average than it was in the 1990s, recent trends suggest there may be little growth globally in this product area for the rest of this decade, according to a recently completed analysis from the Tufts Center for the Study of Drug Development.
